4-bromopiperidine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-bromopiperidine hydrochloride
• 英文别名: 4-Brom-piperidin; Hydrochlorid；4-bromopiperidine;hydrochloride
• 化学式: C₅H₁₀BrN*ClH
• 分子量: 200.506
• InChiKey: VSPDXGMFJVJBAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.56
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-bromopiperidine hydrochloride 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 6.5h， 生成 1-methylethyl 4-(acetylthio)-1-piperidinecarboxylate
  参考文献：
  名称：

  Discovery of 6,7-Dihydro-5H-pyrrolo[2,3-a]pyrimidines as Orally Available G Protein-Coupled Receptor 119 Agonists

  摘要：

  GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119 (GPR119) agonists, and lead optimization efforts led to the identification of 1-methylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate (GSK1104252A) (3), a potent and selective GPR119 agonist. Compound 3 showed excellent pharmacokinetic properties and sufficient selectivity with in vivo studies supporting a role for GPR119 in glucose homeostasis in the rodent. Thus, 3 appeared to modulate the enteroinsular axis, improve glycemic control, and strengthen previous suggestions that GPR119 agonists may have utility in the treatment of type 2 diabetes.

  DOI：

  10.1021/jm301404a
• 作为产物：
  描述：

  4-溴-N-Boc-哌啶 在 乙酰氯 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 18.0h， 以92%的产率得到4-bromopiperidine hydrochloride
  参考文献：
  名称：

  动态多配体催化：极性到自由基交叉策略将炔烃碳硼化扩展为未活化的仲烷基卤化物

  摘要：

  我们描述了基于前所未有的动态多配体配位池的 Cu 催化的双重策略，该池在单个催化循环中触发合作的极性/自由基途径。该策略已被应用于解决 Cu 催化的 B 2 pin 2固有的限制性限制-炔烃的碳硼化——中间体乙烯基-Cu(I) 物质的反应性非常低，这使得传统方法对烷基亲电试剂无效，而不是简单的伯卤化物。通过有机金属中间体中的配体交换实现的交叉策略克服了这一反应性问题，将碳硼化的范围扩大到未活化的仲烷基卤化物，并开辟了获得立体定义的四取代乙烯基硼酸酯的新途径。该方法具有区域选择性和立体选择性，显示出优异的官能团耐受性，并允许在任一反应伙伴处掺入复杂的碳环和杂环片段。

  DOI：

  10.1016/j.chempr.2021.06.002

文献信息

• Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors
  作者：Denise S. Simpson、Kimberly M. Lovell、Anthony Lozama、Nina Han、Victor W. Day、Christina M. Dersch、Richard B. Rothman、Thomas E. Prisinzano

  DOI：10.1039/b905148a

  日期：——

  Further synthetic modification of the furan ring of salvinorin A (1), the major active component of Salvia divinorum, has resulted in novel neoclerodane diterpenes with opioid receptor affinity and activity. A computational study has predicted 1 to be a reproductive toxicant in mammals and is suggestive that use of 1 may be associated with adverse effects. We report in this study that piperidine 21

  Salvinorin A ( 1 )的呋喃环的进一步合成修饰，Salvia divinorum的主要活性成分，产生了具有阿片受体亲和力和活性的新型新氯罗丹二萜。一项计算研究预测1是哺乳动物的生殖毒物，并暗示使用1可能会产生不利影响。我们在这项研究中报告说，哌啶21和硫代吗啉23已被确定为 kappa 阿片受体的选择性部分激动剂。这表明1 可以为配体提供对阿片受体具有良好选择性但降低毒性的可能性。
• Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
  申请人：——

  公开号：US20040063744A1

  公开（公告）日：2004-04-01

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: 1 wherein: Z is 2 Q is selected from the group consisting of: 3 —W— is 4

  这项发明提供了具有药物和生物影响性能的化合物，它们的药物组合物和使用方法。具体而言，该发明涉及具有独特抗病毒活性的新哌啶4-烯基衍生物。更具体地说，本发明涉及用于治疗艾滋病毒和艾滋病的化合物。本发明的化合物为一般式I的化合物： 1 其中： Z是 2 Q是从以下组中选择的： 3 —W—是 4
• Sustainable Route Toward <i>N</i> ‐Boc Amines: AuCl ₃ /CuI‐Catalyzed <i>N</i> ‐ <i>tert</i> ‐butyloxycarbonylation of Amines at Room Temperature
  作者：Yanwei Cao、Yang Huang、Lin He

  DOI：10.1002/cssc.202102400

  日期：2022.2.18

  Boc-kle up: An atom-economic synthesis of N-tert-butoxycarbonyl (N-Boc) amines from amines, t-butanol, and CO is reported at room temperature with commercially available AuCl3/CuI as catalysts. Gram-scale preparation of medicinally important N-Boc amine intermediates is achieved, which demonstrates a potential application prospect in industrial syntheses.

  Boc-kle up :报道了在室温下使用市售的 AuCl 3 /CuI 作为催化剂，由胺、叔丁醇和 CO以原子经济方式合成N-叔丁氧羰基 ( N - Boc) 胺。实现了具有重要药用价值的N -Boc 胺中间体的克级制备，在工业合成中具有潜在的应用前景。
• Imaging Agents for Detecting Neurological Disorders
  申请人：Szardenings Anna Katrin

  公开号：US20110182812A1

  公开（公告）日：2011-07-28

  Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

  本文介绍了公式（I）-（V）的成像剂和用于检测神经系统疾病的方法，其中包括向需要治疗的患者注射能够结合tau蛋白和β-淀粉样肽的公式（I）-（V）化合物。本发明还涉及成像Aβ和tau聚集物的方法，包括引入含有放射性标记的公式（I）-（V）化合物的制剂，并检测与淀粉样沉积物和/或tau蛋白相关联的标记化合物。这些方法和组合物可用于预临床诊断和监测AD和其他神经系统疾病的进展。
• Imaging agents for detecting neurological disorders
  申请人：Szardenings Anna Katrin

  公开号：US08691187B2

  公开（公告）日：2014-04-08

  Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

  本文介绍了公式（I）-（V）的成像试剂和检测神经系统疾病的方法，包括向需要治疗的患者给予能够结合tau蛋白和β-淀粉样肽的公式（I）-（V）的化合物。本发明还涉及成像Aβ和tau聚集体的方法，包括引入含有放射性标记的公式（I）-（V）化合物的制剂，并检测与淀粉样沉积物和/或tau蛋白相关联的标记化合物。这些方法和组合物可以实现AD和其他神经系统疾病的临床前诊断和监测进展。